摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile | 676130-94-2

中文名称
——
中文别名
——
英文名称
2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile
英文别名
2-[4-[[(2S)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]piperazin-1-yl]quinoline-6-carbonitrile
2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile化学式
CAS
676130-94-2
化学式
C27H25N5O2
mdl
——
分子量
451.528
InChiKey
AIBSVCNXTNBLRF-NRFANRHFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    34
  • 可旋转键数:
    3
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    74.5
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile盐酸 作用下, 以 乙醚乙酸乙酯 为溶剂, 生成 2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile dihydrochloride
    参考文献:
    名称:
    Synthesis, Potency, and in Vivo Evaluation of 2-Piperazin-1-ylquinoline Analogues as Dual Serotonin Reuptake Inhibitors and Serotonin 5-HT1A Receptor Antagonists
    摘要:
    On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha(1)-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.
    DOI:
    10.1021/jm900374r
  • 作为产物:
    描述:
    (2R)-quinaldine dioxine brosylate2-(piperazin-1-yl)quinoline-6-carbonitrile三乙胺 作用下, 以 二甲基亚砜 为溶剂, 反应 12.0h, 以72%的产率得到2-(4-{[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile
    参考文献:
    名称:
    Synthesis, Potency, and in Vivo Evaluation of 2-Piperazin-1-ylquinoline Analogues as Dual Serotonin Reuptake Inhibitors and Serotonin 5-HT1A Receptor Antagonists
    摘要:
    On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha(1)-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.
    DOI:
    10.1021/jm900374r
点击查看最新优质反应信息

文献信息

  • [EN] ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS<br/>[FR] DERIVES ARYLPIPERAZINES ANTIDEPRESSEURS DE BENZODIOXANES A FUSION HETEROCYCLIQUE
    申请人:WYETH CORP
    公开号:WO2004024731A1
    公开(公告)日:2004-03-25
    Compounds of the formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    公式I的化合物对治疗抑郁症(包括但不限于重性抑郁障碍、儿童抑郁症和心境恶劣障碍)、焦虑症、恐慌障碍、创伤后应激障碍、经前期情感障碍(也称为经前综合征)、注意力缺陷障碍(伴有和不伴有多动症)、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖、厌食症和暴食症等进食障碍、血管运动性潮红、可卡因和酒精成瘾、性功能障碍及相关疾病方面具有用处。
  • Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans
    申请人:——
    公开号:US20040142926A1
    公开(公告)日:2004-07-22
    Compounds of the formula I: 1 are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    公式I:1的化合物可用于治疗抑郁症(包括但不限于重度抑郁障碍、儿童抑郁症和慢性抑郁症)、焦虑症、恐慌症、创伤后应激障碍、月经前失调症(也称为经前综合症)、注意力缺陷多动障碍(有或没有多动症)、强迫症、社交焦虑症、广泛性焦虑症、肥胖症、饮食失调如厌食症和贪食症、潮红、可卡因和酒精成瘾、性功能障碍及相关疾病的治疗。
  • ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS
    申请人:Wyeth
    公开号:EP1537121A1
    公开(公告)日:2005-06-08
  • US7153849B2
    申请人:——
    公开号:US7153849B2
    公开(公告)日:2006-12-26
  • Synthesis, Potency, and in Vivo Evaluation of 2-Piperazin-1-ylquinoline Analogues as Dual Serotonin Reuptake Inhibitors and Serotonin 5-HT<sub>1A</sub> Receptor Antagonists
    作者:Dahui Zhou、Gary P. Stack、Jennifer Lo、Amedeo A. Failli、Deborah A. Evrard、Boyd L. Harrison、Nicole T. Hatzenbuhler、Megan Tran、Susan Croce、Soo Yi、Jeannette Golembieski、Geoffrey A. Hornby、Margaret Lai、Qian Lin、Lee E. Schechter、Deborah L. Smith、Adam D. Shilling、Christine Huselton、Paul Mitchell、Chad E. Beyer、Terrance H. Andree
    DOI:10.1021/jm900374r
    日期:2009.8.13
    On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha(1)-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.
查看更多